Home » Newsletters » BioWorld MedTech

BioWorld MedTech

May 18, 2011

View Archived Issues

Interventionalists embrace new hypertension therapy

PARIS – It was déjà vu as Europe's largest congress for cardiovascular interventional surgery got underway here. (Medical Device Daily) Read More

Washington roundup: Authors of BMJ article seek tighter UK device recall regs

Panel examines pros/cons of Shared Savings Program

Deals roundup: CryoLife closes circle around Cardiogenesis acquisition

Financings roundup: Ability raises $27M in capital funding

MDD's food for med-tech thought

People in the News

Report from Europe: Curetis increases Series A funding round to €24.5 million

Med-Tech Notes

HIT roundup: Entrada releases options for patient encounter data

Product Briefs

Agreements/contracts: UW, Pharmigene execute warfarin dosing agreement

MDD's Oncology Extra

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...